November 8, 2021 Enzychem Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis Explore further
October 29, 2021 EC-18 Improves Length and Frequency of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer Explore further
October 21, 2021 EC-18 Reduces Duration and Incidence of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer Explore further
October 21, 2021 EC-18 Yields Positive Results for Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer Explore further
October 20, 2021 Enzychem’s EC-18 reduces occurrence of oral mucositis in Phase II trial Explore further
October 20, 2021 Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis Explore further
